Impact of Sarcopenia on Dyspnea in Patients With Asthma
NCT ID: NCT06870890
Last Updated: 2025-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
100 participants
INTERVENTIONAL
2025-03-25
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .
The morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.
The investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of Respiratory Muscle Sarcopenia in Geriatric Individuals
NCT06994598
Respiratory Sarcopenia in Older Adults
NCT06548984
Investigation of Respiratory Muscle Sarcopenia in Adults Diagnosed With Diabetes
NCT07002333
Skeletal Muscle Function in Interstitial Lung Disease
NCT03800017
Respiratory Muscle Assesment in COVID-patients Without Hospitalization
NCT06105450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All the patient included in the study
muscle evaluation
The investigators will evaluate the muscle mass and muscle strenght for all patients included
Dosage
Evaluation of the cinetic of biomarkers during exercise
Cardiopulmonary exercise test
CPET
Questionnaire and Physical Exam
Evaluating dyspnea, anxiety, sleep, physical activity, quality of life
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
muscle evaluation
The investigators will evaluate the muscle mass and muscle strenght for all patients included
Dosage
Evaluation of the cinetic of biomarkers during exercise
Cardiopulmonary exercise test
CPET
Questionnaire and Physical Exam
Evaluating dyspnea, anxiety, sleep, physical activity, quality of life
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient affiliated to a social security scheme.
* Patient capable of giving free, informed, written and signed consent.
* Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment
* ACT asthma control score \< 20
* Patient judged by the investigator to be able to to perform a maximal exercise test.
Exclusion Criteria
* Pregnant or breast-feeding women
* Unstable heart disease
* Patients who have been smoking or have stopped smoking for less than 5 years,
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camille ROLLAND-DEBORD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOI 2023 ROLLAND-DEBORD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.